Response to: Neoadjuvant chemoradiotherapy for oesophageal cancer: Still looking for a challenger to the CROSS regimen

We thank the author of this letter for their commendation regarding our recently published study. We would like to take the opportunity to respond to their points.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uR8qkY
via IFTTT